- Breast Cancer
- Pancreatic Cancer
- Colon Cancer
- Lung Cancer
KRAS Inhibitor Market was valued at USD 90.6 million in 2023 and is expected to grow to USD 682.3 million by 2029, growing at a 23.3% CAGR from 2024 to 2030. KRAS also known as Kirsten rat sarcoma virus, is a gene that provides for making a protein called K-RAS. The mutated form has been found in some types of cancer such as lung cancer, breast cancer, and pancreatic cancer, and is responsible due to self-activation capacity when guanosine exchange factor (GEF) protein displaces GDP from the nucleotide-binding site. The KRAS market-driven pancreatic cancer is extremely fatal.
According to the World Health Organization (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon rectum, and prostate cancers. Rising demand for chemotherapy, radiation therapy, and other therapies accelerated the market, introduction of novel drug development drives the market growth. The diagnostic procedure followed in cancer detection, Bio makers testing which informs therapy options during diseases, and demand for novel drugs and FDA approval as a companion diagnostic application for identification of non-small cell lung cancer may be eligible for treatment with Lumakras creates opportunities in the market. lack of understanding and regarding the benefits of KRAS may limit the expansion in the market which is restraints in the market growth. Geographically, North America held the major market share in 2022 and is expected to dominate the global KRAS inhibitor market in the forecasted years.
Fastest Growing Market
The increasing prevalence of cancer patients across the world is the major market driver in the KRAS inhibitor Market during the forecast period. When mutation in KRAS occurs, greater and cells grow without symptoms causing cancer in the body, the rising incidence of breast cancer and prostate cancer, accelerated development of novel drugs. FDA-approved SOTORASIB to treat non-small lung cancer that has specific mutation. Hence, this will drive the market growth at a significant rate.
The KRAS inhibitor market size is expected to be valued at USD 90.6 million in 2023
The leading players in the KRAS inhibitor market are F. Hoffmann-La Roche Ltd, Qiagen, Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Abbott, NimaGen BV, Agena Bioscience Inc., BML Inc., Takara Bio Inc., New England Biolabs, Amoy Diagnostics Co Ltd, Panagene, EntroGen, Sysmex Corporation, and Biocartis
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and Seven years forecast is presented from 2024 – 2030